Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
AbbVie (NYSE:ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead asset bretisilocin (GM-2505), a novel psychedelic compound in Phase 2 development for major depressive disorder (MDD), for up to $1.2 billion in upfront and milestone payments.
The Phase 2a study demonstrated significant results, with bretisilocin showing a -21.6 point reduction in MADRS depression score versus -12.1 points for the comparator. The compound features a shorter duration of psychoactive experience while maintaining extended therapeutic benefits, addressing key limitations of existing psychedelic treatments.
As part of the deal, Gilgamesh will spin off into Gilgamesh Pharma Inc., retaining its employees and other programs, including its existing collaboration with AbbVie from 2024.
AbbVie (NYSE:ABBV) announced positive topline results from Study 1, the second Phase 3 UP-AA trial evaluating upadacitinib (RINVOQ®) for severe alopecia areata treatment. The study met its primary endpoint with 45.2% of patients on 15 mg and 55.0% on 30 mg achieving ≥80% scalp hair coverage at week 24, compared to 1.5% for placebo.
Key secondary endpoints were also achieved, with 35.2% and 45.8% of patients on 15 mg and 30 mg respectively reaching ≥90% scalp coverage. The safety profile aligned with approved indications, with treatment-emergent serious adverse events occurring in 1.9% (15 mg) and 1.8% (30 mg) of patients. These results mirror the success of the first parallel replicate study (Study 2), strengthening upadacitinib's potential as a treatment for this immune-mediated disease.
AbbVie (NYSE:ABBV) has completed its acquisition of Capstan Therapeutics, gaining access to a pioneering targeted lipid nanoparticle (tLNP) platform and its lead asset CPTX2309.
The acquisition brings a Phase 1 candidate for B cell-mediated autoimmune diseases that generates CD19-specific, CD8+ in vivo CAR-T cells. This innovative therapy aims to achieve durable, drug-free remission through rapid B cell depletion, without requiring lymphodepleting chemotherapy and avoiding traditional CAR-T therapy challenges.
The integration strengthens AbbVie's capability to develop treatments focused on immune system reset and expands the application of Capstan's proprietary technology for in vivo cell programming.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has launched the HA5® Hydra Collagen Hydrating Foaming Cleanser, expanding its SkinMedica® HA5® Hydra Collagen portfolio. The cleanser features the company's proprietary HA5® Hydra Collagen Complex, combining five forms of hyaluronic acid and vegan hydra collagen.
The product uses 100% naturally derived amino acid-based surfactants and Pea Peptides, differentiating itself from traditional foaming cleansers that often contain harsh sulfates. Clinical studies demonstrate that when used with HA5® Hydra Collagen Replenish + Restore Hydrator, the cleanser instantly boosts skin hydration by 30%. The product is priced at $48 MSRP and is available through SkinMedica.com.
["Clinical studies show 30% instant boost in skin hydration when used with companion product", "Product uses 100% naturally derived amino acid-based surfactants, addressing market demand for natural ingredients", "Expands existing successful HA5® product line with complementary offering"]AbbVie (NYSE:ABBV) has announced a $195 million investment to expand its active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois. This expansion is part of AbbVie's broader $10 billion U.S. investment commitment over the next decade.
Construction of the new API facility will begin in fall 2025 and is expected to be fully operational by 2027. The expansion will enhance AbbVie's chemical synthesis capabilities for neuroscience, immunology, and oncology medicines, while supporting over 6,000 American jobs across 11 manufacturing sites.
Allergan Aesthetics (NYSE:ABBV) announces the third annual JUVÉDERM® Day on August 20, 2025, featuring exclusive offers for Allē Members. The celebration includes a Buy One Get One (BOGO) promotion where members can purchase a $75 JUVÉDERM® gift card and receive another $75 gift card free.
The company is also launching a $10,000 sweepstakes for Allē Members who receive JUVÉDERM® treatments between September 20-30, 2025. JUVÉDERM®, the #1 chosen hyaluronic acid filler collection in the U.S., offers six unique FDA-approved formulations for 10 specific facial areas. The program includes flexible payment options through Allē Payment Plans powered by Cherry.
Allergan Aesthetics (NYSE:ABBV) has launched its Faces of Natrelle® campaign, featuring nine women sharing their personal experiences with breast augmentation and reconstruction using Natrelle® breast implants. The campaign, selected through a nationwide casting call, includes diverse stories from breast cancer survivors, mothers, and professionals who chose breast procedures for various personal reasons.
The initiative aims to increase transparency and understanding around breast procedures, which remain among the most popular cosmetic and reconstructive surgeries in the U.S. Natrelle® offers 300 options with five profiles and three gel types for customized results. The campaign will be featured across social media channels and digital platforms, showcasing real stories of transformation and empowerment.
AbbVie (NYSE:ABBV) reported strong Q2 2025 financial results with net revenues of $15.423 billion, up 6.6% year-over-year. The company's immunology portfolio led growth with $7.631 billion in revenues, driven by Skyrizi ($4.423B) and Rinvoq ($2.028B). Neuroscience portfolio revenues grew 24.2% to $2.683 billion.
Key highlights include FDA approval for Rinvoq in giant cell arteritis and Emrelis for non-small cell lung cancer. The company raised its 2025 adjusted EPS guidance to $11.88-$12.08 from $11.67-$11.87, despite a $0.55 per share impact from IPR&D expenses.
Q2 adjusted diluted EPS increased 12.1% to $2.97, while GAAP EPS decreased 32.5% to $0.52, impacted by $0.42 per share from IPR&D expenses.
AbbVie (NYSE:ABBV) announced positive topline results from Study 2 of its Phase 3 UP-AA clinical trial evaluating upadacitinib (RINVOQ®) for severe alopecia areata treatment. The trial achieved its primary endpoint with 44.6% and 54.3% of patients treated with upadacitinib 15mg and 30mg respectively achieving ≥80% scalp hair coverage at week 24, compared to 3.4% for placebo.
Key secondary endpoints were also met, with 36.0% and 47.1% of patients reaching ≥90% scalp coverage in the respective dosage groups. The safety profile aligned with approved indications, with treatment-emergent serious adverse events occurring in 1.4% (15mg) and 2.8% (30mg) of patients. Common side effects included acne, nasopharyngitis, and upper respiratory tract infection. Results from Study 1 are expected in Q3 2025.
[ "Strong efficacy with 54.3% of patients achieving ≥80% scalp hair coverage at highest dose", "First pivotal program to achieve complete scalp hair regrowth (SALT=0)", "Successful achievement of both primary and key secondary endpoints", "Generally consistent safety profile with approved indications" ]AbbVie (NYSE:ABBV) has submitted a supplemental New Drug Application (sNDA) to the FDA for a novel combination therapy using VENCLEXTA® (venetoclax) and acalabrutinib to treat previously untreated Chronic Lymphocytic Leukemia (CLL) patients.
The submission is supported by the Phase 3 AMPLIFY trial, which demonstrated statistically significant improvement in progression-free survival compared to standard chemoimmunotherapy. If approved, this would be the first all-oral, fixed-duration combination regimen of these drugs for CLL treatment, offering patients the potential benefit of treatment-free periods.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
